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In the early 1980s, the oncogene
field was in transition. The
biological properties of more than 20
oncogenes had been described in
animal tumor models and cell
transformation assays. Attention was
shifting to the question of how
these genes actually function. In a
few cases, it was obvious. The v-Sis
protein (encoded by the
transforming gene of simian sarcoma
virus) was shown to be related to
platelet-derived growth factor and
erbB (the oncogene from avian
erythroblastosis virus) was found to
encode a receptor for epidermal
growth factor. The transforming Ras
protein was known to bind GTP.
This put Ras in a class with the
classical signal transducing
G-proteins, elongation factors and
tubulin but did not clarify its
mechanism of action.
The biochemical analysis that
was needed to answer such
questions was still in its early stages
when I decided to enter the field.
Two main questions were being
addressed: first, how do oncogenic
proteins differ from their normal
cellular counterparts? This question
involved comparison of biochemical
properties of normal and mutant
proteins — a relatively logical
process, and one that was made
practical by the development of
recombinant methods of producing
these proteins. Second, how do
these proteins transform cells? This
was more of a guessing game. For
Ras, it meant a long and relatively
fruitless search for proteins that
interact with Ras in its active state,
and could therefore be Ras
‘effectors’.
It was clear that Ras plays a major
part in human cancer; by 1983,
activating mutations in ras genes
(single amino acid changes that
seemed to make the mutant Ras
proteins overactive) had been
described in a variety of cell lines
and tumors. (And this was before
PCR had even been invented.) To
me, with a degree in biochemistry
and a job in a biotechnology
company, it seemed an ideal moment
to apply biochemistry to the question
of Ras function. This was a real
turning point for me. In 1984, I
wound down my work on
mammalian expression systems and
characterization of β-interferon and
geared up to enter the Ras field.
The attention of my group was
focussed on the biochemical
properties of normal and oncogenic
forms of Ras proteins produced in
Escherichia coli. We were inspired and
encouraged by four papers that
revealed a dramatic difference
between the two: the normal Ras
protein could hydrolyze GTP to
GDP; an oncogenic mutant (glycine
to valine at codon 12), could not.
This lead to a beautifully simple
model. Ras proteins are simple
switches. They are on when bound
to GTP, and off when bound to GDP.
Normal Ras turns itself off by
converting GTP to GDP through its
built-in GTPase activity; oncogenic
Ras is stuck in the on position
because its built-in GTPase is
defective (see Figure 1).
This brilliant model was
inspiring but also provocative
because it raised further questions.
Most troubling to us was the fact
that the mutant protein did, in fact,
retain some GTPase activity: it was
only about 8-fold less active than
wild-type Ras. This hardly seemed
sufficient to account for its awesome
transforming power. Moreover, the
mutant we were working on, the
aspartate-12 mutant, was just as
powerful at transforming cells yet it
was only about 3-fold less active
than wild-type Ras in hydrolyzing
GTP. We therefore started to wonder
whether the GTPase model needed
some modification.
A strong prediction of the model
was that normal Ras should be in the
off state (bound to GDP) in normal
cells, whereas the oncogenic mutant
should mostly be in the on state
(bound to GTP). Using various
technical tricks and an awful lot of
radioactive phosphorous, we
confirmed this.
But in the process, we discovered
that the aspartate-12 mutant was
fully loaded with GTP, just like the
valine-12 mutant, even though its
GTPase activity as measured in the
test tube was not much different
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Figure 1
Model for the Ras protein switch mechanism, which is defective in cells expressing mutant Ras
proteins. This led to experiments that identified GAP, the GTPase-activating protein.
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from that of wild-type Ras. This
suggested to us that GTPase rates
measured in the test tube did not
reflect rates in living cells, so we set
about measuring GTPase rates in
vivo. We discovered that in vivo,
normal Ras proteins hydrolyze GTP
hundreds of times faster than in the
test tube and hundreds of times
faster than oncogenic mutants. We
went on to identify a cellular factor
that accelerates GTP hydrolysis and
called it GAP (GTPase-activating
protein). With the help of GAP,
normal Ras proteins turn themselves
off extremely efficiently, whereas
oncogenic Ras proteins do, indeed,
stay locked in the on position.
GAP, as the first protein
identified that regulates a proto-
oncogene, represented an early step
in the process of dissecting signal
transduction pathways. Others used
it to define the rules of engagement
with tyrosine phosphoproteins and it
was found to be related to the gene
responsible for neurofibromatosis
type 1. Now it’s known that virtually
all Ras-like proteins, as well as
classical G-proteins, are controlled by
their own GAPs.
These were great times for
biochemists and molecular biologists;
the parallel development of oncogene
biology and recombinant DNA
offered many opportunities to make
useful contributions. And the
geneticists who started the oncogene
revolution were by no means left in
the dust. Dissection of signalling
pathways and oncogene function
relied heavily on genetic model
systems. In fact, the research groups
that made most progress in this period
contained each of these disciplines,
and the collegiate interactions among
specialists in each area has been one
of the many pleasures of working in
this field. If all these efforts lead to a
new cancer therapy, that would be the
greatest pleasure of all.
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Single calponin
homology domains
are not actin-binding
domains
Mario Gimona* and
Steven J. Winder†
Calponin homology (CH) domains
are novel protein modules
identified in a variety of proteins
ranging from actin cross-linking
proteins to signalling molecules
proposed to function as autonomous
actin-binding motifs [1]. The
assumption was that the archetypal
smooth muscle calponin (CaP)
binds to actin via its single amino-
terminal CH domain. In their
original paper, Castresana and
Saraste [1] identified the CH
domain via statistical analyses of
sequences related by secondary
structure, and on the basis of this
analysis suggested that Vav [2] — a
guanine nucleotide exchange factor
for the Rho-family GTPase Rac —
and other signalling molecules use
the CH domain to associate with
actin. In the wake of this
suggestion, the hypothesised actin-
binding activity of the single CH
domain was invoked by several
authors as a means by which
signalling molecules such as IQGAP
could be targeted to the actin
cytoskeleton [3–5]. 
Misconceptions about the actin-
binding function of CH domains
have been compounded by their
identification in the actin-binding
domains (ABDs) of classical actin
cross-linking proteins [6]. But in
ABDs they occur in tandem repeats
and share only about 30% identical
residues with the CH domains of the
calponin family. The first and
second CH domains in ABDs differ
not only in sequence, but also
markedly in their affinities for actin,
as shown for α-actinin [7]. Further,
the amino-terminal CH domains of
utrophin and dystrophin are able to
bind to F-actin, whereas the
carboxy-terminal CH domains bind
F-actin with very low affinity or not
at all ([8]; S.J.W., unpublished
observations). 
Although IQGAP is able to
cross-link F-actin in vitro and
localises to membrane ruffles of
cultured cells [9], no conclusive
evidence has been brought forward
for the direct association of a single
CH domain with F-actin. Instead,
we have shown that the single CH
domain of CaP [10], as well as that
of the CaP-related protein SM22
(R Mital, M.G., unpublished
observations), fails to target to
either stress fibres or membrane
ruffles of transfected fibroblasts,
and that two independent actin-
binding sites outside the CH
domain are responsible for F-actin
binding in CaP [10]. Furthermore, a
bacterially expressed construct
corresponding to the CH domain of
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CaP and comprising residues
28–134 does not bind to F-actin in
an in vitro sedimentation assay
(S.J.W., unpublished observations). 
We have also found that Vav
induces and associates with
peripheral and dorsal membrane
ruffles, but not filopodia, and that
deletion of the amino-terminal CH
domain does not alter its localisation
pattern (W. Kranewitter, M.G.,
unpublished observations). Together,
these results indicate that the single
amino-terminal CH domain is
neither sufficient nor necessary for
actin binding of CaP [10] and imply
that single CH domains are unlikely
to serve as autonomous actin-
targeting motifs in monomeric
signalling molecules. Nevertheless,
based on F-actin co-sedimentation
studies using truncated glutathione-
S-transferase (GST) fusion proteins,
two groups [3,11] have demonstrated
recently that the actin-binding
activity for IQGAP 1 and its putative
yeast homologue Iqg1 resides within
the CH-domain-embracing amino-
terminal 216 and 538 residues,
respectively. The CH domain
occupies only 100 of these residues.
The ability to cross-link F-actin
depends on the potential of IQGAP
to oligomerise via the IQGAP-
specific repeats, pointing towards a
possible requirement for a second
domain for actin binding in vivo. It is
thus conceivable that single CH
domains can cooperate synergistically
with other modules to mediate
F-actin binding. 
In view of current
misapprehensions about CH
domains, we have recently analysed
the sequences of all CH-domain-
containing proteins currently
available. The analysis has shown
that amino-terminal (type 1),
carboxy-terminal (type 2), and single
CH domains group into individual
‘families’ [12]. Most importantly, we
were able to show that all single
CH-domain-containing proteins,
namely CaP, SM22, IQGAP and Vav,
display a higher degree of sequence
similarity in their respective CH
domains to the members of the same
subfamilies than to either of the CH
domains found in any ABD. Hence,
the function of a CH domain in
signalling molecules is more likely to
be gleaned from studies on CaP than
on the ABDs of actin cross-linking
proteins and related proteins. 
We thus propose that CH
domains display a different function
when present in single as compared
to tandem motifs, and that different
classes of proteins contain CH
domains of different ‘quality’. A
similar phenomenon has been
reported for another 100 amino acid
protein module, the pleckstrin
homology (PH) domain [13,14]. The
two PH domains of the archetypal
pleckstrin, situated at the amino-
terminal and carboxy-terminal ends
of the molecule, are functionally
divergent, and PH domains from
other proteins fail to functionally
substitute for the amino-terminal PH
domain in pleckstrin itself [15]. 
We conclude that a careful re-
evaluation of CH domains is
required with respect to actin-
binding properties, especially for
monomeric proteins that contain only
one CH domain. 
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